论文部分内容阅读
目的 探讨非诺贝特对非酒精性脂肪肝(NAFLD)患者肝纤维化指标、脂代谢的影响。方法 选取睢县中医院87例NAFLD患者,随机分为对照组43例和观察组44例,对照组口服456 mg多烯磷脂酰胆碱胶囊治疗,观察组口服0.2 g非诺贝特治疗,均治疗3个月。比较两组治疗效果及肝纤维化指标[Ⅲ型前胶原(PCⅢ)、层黏蛋白(LN)、透明质酸(HA)]、脂代谢指标[总胆固醇(TC)、甘油三脂(TG)]水平变化情况。结果 观察组治疗总有效率为90.91%,高于对照组的72.09%,差异有统计学意义(P<0.05);治疗后观察组PCⅢ、LN、HA及TC、TG水平均低于对照组,差异有统计学意义(P<0.05)。结论 非诺贝特可改善NAFLD患者肝纤维化指标及脂代谢水平,提高疗效。
Objective To investigate the effects of fenofibrate on liver fibrosis and lipid metabolism in patients with non-alcoholic fatty liver disease (NAFLD). Methods 87 cases of NAFLD patients from Shexian Hospital were randomly divided into control group (n = 43) and observation group (n = 44). The control group received oral administration of 456 mg polyene phosphatidylcholine capsule, and the observation group received 0.2 g fenofibrate Treatment for 3 months. The therapeutic effects and the indexes of liver fibrosis (PC Ⅲ, laminin and HA), lipid metabolism (TC, TG, ] Level changes. Results The total effective rate of observation group was 90.91%, higher than that of control group (72.09%), the difference was statistically significant (P <0.05); after treatment, PCⅢ, LN, HA and TC, The difference was statistically significant (P <0.05). Conclusion Fenofibrate can improve liver fibrosis index and lipid metabolism in patients with NAFLD and improve the curative effect.